FDA Plans Tailored Framework to Guide Rare Disease Drug Development

The Food and Drug Administration has introduced a new effort to overhaul how it evaluates therapies for rare diseases. Announced on Wednesday, the Rare Disease Framework Initiative aims to replace broad, uniform rules with standards tailored to specific medical conditions. In an agency white paper, officials said the project will assess policies across the entire development process, ranging from pre-clinical research to requirements enforced after a medicine reaches the market.

Developing treatments for rare conditions carries unusual hurdles. Sponsors fail more than 90 percent of the time when bringing any new drug forward, but rare illnesses feature small patient groups, limited clinical knowledge, and fewer reliable biomarkers to track in trials. Around 30 million people in the United States live with a rare disease, yet the FDA noted that only about 5 percent of recognized conditions had an approved treatment as of last year.

Shifting regulatory approaches

The initiative follows years of shifting regulatory approaches and leadership turnover. BioPharma Dive reports that Peter Marks, the former head of the FDA's drug evaluation center, championed many rare disease drugs but drew criticism from observers who felt standards had grown too flexible. In 2025, one of those critics, Vinay Prasad, took charge of the agency's biologics center. Under President Trump, Prasad and then-Commissioner Marty Makary adopted stricter stances that created friction and confusion for biotechnology firms and patient advocates. Both Prasad and Makary have departed, and the FDA has yet to confirm a permanent leader while walking back several contentious decisions.

To build the new framework, the agency plans to gather feedback from patients and medical specialists at an October 28 meeting at its Silver Spring, Maryland campus. Although the FDA has not released an official timetable for its early recommendations, Bloomberg News reported that officials are aiming for February. Leerink Partners analyst Joseph Schwartz noted that the initiative does not lower review standards, but could reduce uncertainty for drugmakers if it provides enduring rules similar to past measures like orphan drug designations and priority review vouchers.